BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
A Timeline of Rising Antisemitism in Australia - 2Pick Your Number one sort of blossom
- 3AstraZeneca to invest $2 billion as part of US manufacturing push
- 4Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
- 5Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- Survey: Protected And Versatile Men's Razor
- Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- Japan deploys the military to counter a surge in bear attacks
- Teen drug use remains low, but survey finds small rise in heroin and cocaine use
- Orbán orders stop to gas deliveries to Ukraine via Hungary from July
- 6 Tire Brands Reasonable for Seniors
- Manual for Tracking down the Immaculate Magnificence of Focal Asia
